Intravenous adrenaline or vasopressin in sudden cardiac arrest: a literature review

Sudden cardiac arrest remains a leading cause of mortality globally, yet the optimal pharmacological intervention for resuscitation remains debated. The chain of survival framework emphasizes the delivery of early advanced care to improve patient outcomes. Intravenous adrenaline has served as the primary therapeutic agent for over a century. That uncertainty drove investigators to question the clinical efficacy of this long-standing practice. No prior work had resolved whether alternative agents might offer superior survival benefits. Prior research has shown that adrenaline improves coronary perfusion pressure in controlled settings. This gap motivated a systematic evaluation of existing clinical and experimental data. The current literature review synthesizes findings to clarify the roles of these common resuscitation drugs.

The aim of this study was to evaluate the clinical effectiveness of adrenaline and vasopressin in sudden cardiac arrest. Researchers sought to determine if the long-standing use of adrenaline is supported by robust evidence. This gap motivated a systematic review of existing clinical and experimental data. The authors investigated whether vasopressin serves as a more effective alternative for resuscitation. That uncertainty drove the need to synthesize findings from various clinical trials. The study also examined whether high-dose adrenaline offers any advantage over standard dosing. By clarifying these issues, the authors intended to guide future clinical research priorities. This work addresses the necessity of evidence-based pharmacological interventions in emergency care settings.

The review approach involved a comprehensive systematic search of the medical literature. Investigators identified relevant clinical trials and experimental studies published on this topic. The team synthesized findings from human and animal research to evaluate drug efficacy. This methodology focused on comparing standard pharmacological practices against emerging alternatives. Reviewers assessed the quality of evidence regarding coronary perfusion pressure and patient survival. The design prioritized studies that directly addressed the utility of these intravenous agents. Researchers excluded non-relevant data to maintain a strict focus on resuscitation outcomes. This structured process ensured a thorough examination of the current scientific landscape.

Key findings from the literature indicate that adrenaline has not been shown to improve survival in clinical trials. Experimental evidence confirms that adrenaline does increase coronary perfusion pressure during resuscitation attempts. Extensive trials demonstrated that high-dose adrenaline provides no benefit compared to standard doses. Vasopressin appears more effective than adrenaline in animal models for treating resistant ventricular fibrillation. However, no clinical trial has yet proven that vasopressin is superior to adrenaline in humans. The data suggest a significant gap between physiological improvements and actual patient survival outcomes. Current evidence remains insufficient to recommend a change from established adrenaline protocols. The findings highlight the necessity for more rigorous human studies in this field.

The authors propose that current clinical evidence fails to demonstrate a survival advantage for adrenaline. Synthesis and implications suggest that high-dose adrenaline provides no benefit over standard dosing regimens. Researchers note that vasopressin demonstrates potential efficacy in animal models of resistant ventricular fibrillation. However, clinical trials have not yet established vasopressin as a superior alternative to adrenaline. The review highlights a persistent lack of definitive data regarding pharmacological superiority in human subjects. Future efforts should prioritize large-scale randomized controlled trials to evaluate vasopressin effectiveness. The authors maintain that early cardiopulmonary resuscitation and defibrillation remain the most effective strategies for improving survival. Clinical practice should continue to focus on these established interventions while awaiting further high-quality evidence.